cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stoke Therapeutics
5 own
6 watching
Current Price
$9.47
$0.79
(9.1%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
597.51M
52-Week High
52-Week High
17.58000
52-Week Low
52-Week Low
4.090000
Average Volume
Average Volume
1.23M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization597.51M
icon52-Week High17.58000
icon52-Week Low4.090000
iconAverage Volume1.23M
iconDividend Yield--
iconP/E Ratio--
What does the Stoke Therapeutics do?
Stoke Therapeutics, Inc. are pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. They are developing novel antisense oligonucleotide, or ASO, medicines that target ribonucleic acid, or RNA, and modulate precursor-messenger RNA, or pre-mRNA, splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. They utilize their proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, to design ASOs to upregulate the expression of protein by individual genes in a patient. Their approach is designed to allow them to deliver in a highly precise, durable and controlled manner disease-modifying therapies to a broad range of relevant tissues, including the central nervous system, or CNS, eye, kidney and liver. They designed their lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. With a well-defined patient population based on routine genetic testing and learnings from recently approved drugs for the treatment of Dravet syndrome to inform the clinical and regulatory pathways for STK-001, they anticipate an efficient clinical program for STK-001. They plan to submit an investigational new drug application, or IND, for STK-001 by early 2020 and expect to initiate a Phase 1/2 clinical trial in the first half of 2020. They intend to nominate a second candidate to treat an additional genetic disease for preclinical development by the first half of 2020. Stoke Therapeutics, Inc. were incorporated under the laws of the State of Delaware in June 2014 under the name ASOthera Pharmaceuticals, Inc. They subsequently changed their name to Stoke Therapeutics, Inc. on May 18, 2016. Their principal executive office is located at 45 Wiggins Avenue, Bedford, Massachusetts, 01730.
Read More
How much money does Stoke Therapeutics make?
News & Events about Stoke Therapeutics.
Market News Video
1 year ago
In trading on Friday, shares of Stoke Therapeutics Inc (STOK) crossed above their 200 day moving average of 11.29, changing hands as high as 11.46 per share. Stoke Therapeutics Inc shares are currently trading up about 4.9% on the day...
Zolmax
1 year ago
Stoke Therapeutics, Inc. (NASDAQ:STOK Get Rating) SVB Leerink issued their Q3 2023 EPS estimates for Stoke Therapeutics in a research report issued on Monday, March 6th. SVB Leerink analyst R. Li anticipates that the company will earn ($0.73) per share for the quarter. The consensus estimate for ...
Ticker Report
1 year ago
Stoke Therapeutics, Inc. (NASDAQ:STOK Get Rating) Stock analysts at Jefferies Financial Group issued their Q3 2023 earnings estimates for Stoke Therapeutics in a report issued on Monday, March 6th. Jefferies Financial Group analyst S. Jeong anticipates that the company will earn ($0....
Ticker Report
1 year ago
Stoke Therapeutics, Inc. (NASDAQ:STOK Get Rating) Equities researchers at Jefferies Financial Group issued their Q1 2023 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a report released on Monday, March 6th. Jefferies Financial Group analyst S. Jeong ...
Zolmax
1 year ago
Stoke Therapeutics, Inc. (NASDAQ:STOK Get Rating) Stock analysts at HC Wainwright issued their Q1 2023 EPS estimates for shares of Stoke Therapeutics in a report issued on Tuesday, March 7th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.72) per share for the...
Frequently Asked Questions
Frequently Asked Questions
What is Stoke Therapeutics share price today?
plus_minus_icon
Can Indians buy Stoke Therapeutics shares?
plus_minus_icon
How can I buy Stoke Therapeutics shares from India?
plus_minus_icon
Can Fractional shares of Stoke Therapeutics be purchased?
plus_minus_icon
What are the documents required to start investing in Stoke Therapeutics stocks?
plus_minus_icon
What is today’s traded volume of Stoke Therapeutics?
plus_minus_icon
What is today’s market capitalisation of Stoke Therapeutics?
plus_minus_icon
What is the 52-Week High and Low Range of Stoke Therapeutics?
plus_minus_icon
What percentage is Stoke Therapeutics down from its 52-Week High?
plus_minus_icon
What percentage is Stoke Therapeutics up from its 52-Week Low?
plus_minus_icon
Current Price
$9.47
$0.79
(9.1%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PHATHOM PHARMACEUTICALS INC
PHATHOM PHARMACEUTICALS INC
$7.12
$0.33 (4.86 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$13.89
$0.61 (4.59 %)
Taysha Gene Therapies Inc
Taysha Gene Therapies Inc
$1.64
$0.02 (1.23 %)
Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc.
$6.38
$0.05 (0.71 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
PHATHOM PHARMACEUTICALS INC
PHATHOM PHARMACEUTICALS INC
$7.12
$0.33 (4.86 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$13.89
$0.61 (4.59 %)
Taysha Gene Therapies Inc
Taysha Gene Therapies Inc
$1.64
$0.02 (1.23 %)
Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc.
$6.38
$0.05 (0.71 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00